| Species |
Mouse |
| Protein Construction |
CCL25 (Gln24-Asn144)
Accession # O35903 |
|
| Purity |
> 95% as analyzed by SDS-PAGE
> 95% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
The biological activity determined by a chemotaxis bioassay using human monocytes is in a concentration range of 5.0-50.0 ng/ml. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
14.1 kDa |
| Formulation |
Lyophilized from a 0.2 µm filtered solution in 20 mM PB, pH 7.4, 150 mM NaCl. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -20°C or -70°C. Upon reconstitution, the product should be stable for up to 1 week at 2-8°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CCL25 is a new member of the CC family chemokine. It is also called Thymus-expressed chemokine (TECK) because it is restricted produced by thymus and intestine. Especially, the dendritic cells derived from thymus but not bone marrow had been identified to be the source of CCL25. By binding with CCR9, it elicits its effects of chemotactic for thymocytes, macrophages, and dendritic cells. Additionally, CCL25 takes part in regulating the development of T-cells. |
| Synonyms |
SCYA25; Ckb15 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
